Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations A Pediatric MATCH Treatment Trial
Study Type: Treatment
Phase: II
NCTID: NCT03220035
Principal Investigator:
Kevin Ginn
Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 ZEN-3694, and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors ComBET
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Study Type: Treatment
Phase: II
NCTID: NCT05633615
Principal Investigator:
Marc Hoffmann
A Multicenter, Open-Label, Phase Ia/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors
Study Type: Treatment
Phase: I
NCTID: NCT06596473
Principal Investigator:
Weijing Sun
A Phase 1 Study of SynKIR-310, Autologous T cells Transduced with CD19 KIR-CAR, in Participants with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study Type: Treatment
Phase: I
NCTID: NCT06544265
Principal Investigator:
Joseph McGuirk
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Alpelisib BYL719 in Combination with Nab-Paclitaxel in Patients with Advanced Triple Negative Breast Cancer with Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha PIK3CA Mutation or Phosphatase and Tensin Homolog Protein PTEN Loss Without PIK3CA Mutation
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Ind 134427 Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Phase II Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
An Open-Label, Multicenter, Phase IB /II Study of Rebastinib DCC-2036 in Combination with Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors.
A Phase III Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features
Study Type: Treatment
Phase: III
NCTID: NCT05382338
Principal Investigator:
Keith August